AstraZeneca Exceeds Earnings and Revenue Estimates, Reaffirms FY26 Outlook
AstraZeneca PLC (AZN) reported Q1 Non-GAAP earnings per share of $2.58, surpassing estimates by $1.31, and revenue of $15.29 billion, which exceeded expectations by $370 million. The company also noted a 12% increase in core operating profit and a core tax rate of 21%, with unchanged expectations for the full year core tax rate.
Tickers: $AZN
Topics: earnings financial performance non-GAAP EPS profit revenue